117 related articles for article (PubMed ID: 15794199)
21. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
22. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome.
Callaghan R; Prabu A; Allan RB; Clarke AE; Sutcliffe N; Pierre YS; Gordon C; Bowman SJ;
Rheumatology (Oxford); 2007 Jan; 46(1):105-11. PubMed ID: 16728437
[TBL] [Abstract][Full Text] [Related]
23. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.
Verstappen SM; Jacobs JW; van der Heijde DM; van der Linden S; Verhoef CM; Bijlsma JW; Boonen A
Ann Rheum Dis; 2007 Jun; 66(6):727-31. PubMed ID: 17172249
[TBL] [Abstract][Full Text] [Related]
24. The economic burden of depression among adults with rheumatoid arthritis in the United States.
Li N; Chan E; Peterson S
J Med Econ; 2019 Apr; 22(4):372-378. PubMed ID: 30663460
[TBL] [Abstract][Full Text] [Related]
25. Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09.
Hallert E; Husberg M; Kalkan A; Bernfort L
Scand J Rheumatol; 2016 Oct; 45(5):371-8. PubMed ID: 26854719
[TBL] [Abstract][Full Text] [Related]
26. Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists?
Gabriel SE; Wagner JL; Zinsmeister AR; Scott CG; Luthra HS
Arthritis Rheum; 2001 Jul; 44(7):1504-14. PubMed ID: 11465700
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
von Scheele B; Peña B; Wong J; Niculescu L
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii53-9. PubMed ID: 14585918
[TBL] [Abstract][Full Text] [Related]
28. Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.
Kirchhoff T; Ruof J; Mittendorf T; Rihl M; Bernateck M; Mau W; Zeidler H; Schmidt RE; Merkesdal S
Rheumatology (Oxford); 2011 Apr; 50(4):756-61. PubMed ID: 21149243
[TBL] [Abstract][Full Text] [Related]
29. Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.
Rai SK; Aviña-Zubieta JA; McCormick N; De Vera MA; Lacaille D; Sayre EC; Choi HK
Arthritis Care Res (Hoboken); 2017 May; 69(5):758-762. PubMed ID: 27565008
[TBL] [Abstract][Full Text] [Related]
30. How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis?
Tuominen R; Tuominen S; Möttönen T
Scand J Rheumatol Suppl; 2011; 125():12-6. PubMed ID: 21529305
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
32. Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs.
Puchner R; Hochreiter R; Pieringer H; Vavrovsky A
BMC Musculoskelet Disord; 2017 Jan; 18(1):7. PubMed ID: 28061896
[TBL] [Abstract][Full Text] [Related]
33. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
34. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
Kvamme MK; Lie E; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
[TBL] [Abstract][Full Text] [Related]
35. [Epidemiology, resource use and costs of rheumatoid arthritis in Argentina].
Secco A; Alfie V; Espinola N; Bardach A
Rev Peru Med Exp Salud Publica; 2020 Dec; 37(3):532-540. PubMed ID: 33295558
[TBL] [Abstract][Full Text] [Related]
36. Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden.
Miranda LC; Santos H; Ferreira J; Coelho P; Silva C; Saraiva-Ribeiro J;
Acta Reumatol Port; 2012; 37(2):134-42. PubMed ID: 23149635
[TBL] [Abstract][Full Text] [Related]
37. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
38. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A
Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069
[TBL] [Abstract][Full Text] [Related]
39. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France.
Beresniak A; Gossec L; Goupille P; Saraux A; Bamberger M; Bregman B; Dupont D
J Rheumatol; 2011 Mar; 38(3):439-45. PubMed ID: 21123324
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
